Alan Ezekowitz, MBChB, D.Phil., FAAP
President, Co-Founder, CEO
Alan Ezekowitz MBChB, D.Phil., FAAP, joined Cardinal Partners as an Entrepreneur-in-Residence in April 2011. He is Co-Founder, President and CEO of Abide Therapeutics, a company co-founded by Professors Dale Boger and Ben Cravatt from the Scripps Research Institute.
He was previously Senior Vice President and Franchise Head, Bone, Respiratory, Immunology, Endocrine, Dermatology and Urology at Merck Research Laboratories; he joined Merck in 2006 and retired in March 2011. At Merck, he was responsible for the overall scientific direction of the drug discovery and development process from target identification through the life cycle management for approved drugs for Merck’s key therapeutic areas of immunology, respiratory disease, endocrine disorders, urology, dermatology and woman’s health. Prior to Merck, Alan worked at Massachusetts General Hospital, where he had served as chief of Pediatric Services at the MassGeneral Hospital for Children and the Partners Healthcare System. He also served on many senior committees including the Executive Committee on Research the Massachusetts General Hospital, which he chaired. He also served as the Charles Wilder Professor of Pediatrics at the Harvard Medical School and chaired the committee that led to the establishment of the Academy at the Harvard Medical School where he served as a Scholar and Founding member.He served on the Board of Directors of the Partners Healthcare System and MassGeneral Physicians Organization. He also served on the Boards of Anika Therapeutics and Natimmune, a biotech company that he founded. He also serves on the Board of Directors of Oxagen, and Abide Therapeutics. He is a member of the American Society of Clinical Investigation, the Association of American Physicians, the American Pediatric Society and a Fellow of AAAS. He served on NIH Subcommittee on Biodefense; NIH Subcommittee on Vaccine Adjuvants; National Academy of Sciences panel on antibiotic resistance: National Academy of Science panel examining academic pharmaceutical partnerships; Council AAAS Section for Medical Sciences that reviews policy and membership for the AAAS. ARISE 2 task force of American Academy of Arts & Science Member that is evaluating the impact of federal and industrial funding of science, engineering, and medicine on American universities.
He is a pioneer in the field of innate immunity and has over 150 publications. His work has enhanced the understanding of innate immunity. In particular his group played a major role in defining the structure function of the mannose binding lectin and the macrophage mannose receptor. In addition his work on phagocyte biology spanned from a very basic understanding of the complex regulation of phagocytosis using flies as a model system, to the translation to human phagocyte biology and includes the application of this knowledge into an FDA approved treatment for Chronic Granulomatous Disease, a phagocytic disorder in humans. In 2008 he was honored with the establishment R. Alan Ezekowitz Professorship in Pediatrics at the Harvard Medical School.
Dr. Ezekowitz received his medical training at the University of Cape Town in South Africa and was awarded a Doctor of Philosophy degree from Oxford University where he also completed a postdoctoral fellowship. At Children’s Hospital in Boston, he completed a second postdoctoral fellowship in the Division of Hematology and Oncology and his clinical training in pediatrics. He was on the staff of the Children’s Hospital of Boston prior to moving to the Massachusetts General Hospital.
Dale Boger, Ph.D.
Richard and Alice Cramer Professor of Chemistry
at The Scripps Research Institute
Dale Boger received his B.Sc. in chemistry from the University of Kansas, Lawrence, Kansas (1975, with highest distinction and honors in chemistry) and his Ph.D. in chemistry from Harvard University (1980) under the direction of E. J. Corey.
John K. Clarke
Managing Partner. Princeton, NJ Office
John Clarke has a 30 year record of early-stage venture capital investment success. John co-founded Cardinal Partners in 1997 and currently serves as a Managing Partner of the firm. John leads Cardinal’s life sciences investment efforts and has had an extraordinary record of success.
John received his B.A. in Economics and Biology from Harvard University and his M.B.A. from the Wharton School at the University of Pennsylvania.
Benjamin F. Cravatt, Ph.D.
Professor and Chair of the Department of Chemical Physiology
at The Scripps Research Institute
Dr. Cravatt’s research group is interested in understanding the roles that enzymes play in physiological and pathological processes, especially as pertains to the nervous system and cancer. To address this challenge, they develop and apply an array of biochemical, chemical, and genetic technologies.
Todd Jones, Ph.D.
Vice President, Drug Discovery
Todd Jones, Ph.D., has over twenty years of experience in drug discovery and development in both pharmaceutical and biotechnology companies. He is currently a co-founder and Vice President, Drug Discovery, for Abide Therapeutics, in La Jolla, California.
Previously Todd served as Vice President of Chemistry & Enabling Technologies at Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) where he had responsibility for establishing, building and guiding Medicinal Chemistry, Biology Enabling Research Technologies (Compound Logistics, Developability, Drug Metabolism & Pharmacokinetics, Genomics and High Throughput Screening), Scale-up Chemistry, Analytical Chemistry, and Computational Chemistry. During Todd’s leadership tenure, the J&JPRD La Jolla site generated over thirty new molecular entities that were accepted into development with more than fifteen advancing into human clinical trials.
Prior to J&JPRD, Todd held positions of increasing responsibility at Ontogen Corporation, an automated high-throughput chemical-synthesis drug discovery company, and Ligand Pharmaceuticals, a cutting-edge drug discovery biotechnology company, in San Diego. Todd began his pharmaceutical career at Merck Research Laboratories in Rahway, NJ, where he gained experience in process and medicinal chemistry. Todd has been involved in projects spanning anti-parasitic, inflammatory, metabolic, neuroscience, oncology, pain, and reproductive medicine therapeutic areas. He is an inventor on more than ninety issued United States patents and a co-author on over sixty peer-reviewed scientific publications.
Todd earned his B.S. in chemistry from the Colorado School of Mines in Golden, CO, followed by a Ph.D. in chemistry from the University of Illinois at Urbana-Champaign, IL, in Professor Scott Denmark’s laboratories. He was awarded a National Institutes of Health postdoctoral fellowship at Harvard University in Cambridge, MA, under the direction of Professor David Evans.
Vice President, Product & Business Development at Maxygen, Inc.
Keith Lenden is currently the Vice President of Product and Business Development at Maxygen where he’s building a public-private partnership with the US Government to develop medical countermeasures against radiological or nuclear attack.
Paul Schimmel, Ph.D.
Ernest and Jean Hahn Professor
at The Skaggs Institute for Chemical Biology
at The Scripps Research Institute
Dr. Schimmel earned his Ph.D. in biology at MIT in 1966 and was formerly the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at MIT.